Author: Li, Guanghua; Wang, Na; Sun, Chuanjin; Li, Bo
Title: Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I–III gastric cancer Document date: 2014_3_28
ID: 1hps5owh_19
Snippet: Although the incidence and mortality rate of GC have fallen over the past several decades, GC is still the fourth most common cancer and the second leading cause of cancer-related death in the world [22, 23] . Disappointingly, little improvement has been achieved within the past several decades despite advances in tumor diagnosis and treatment [24, 25] . Given the high failure rate of conventional treatment strategies, many cancer-related molecul.....
Document: Although the incidence and mortality rate of GC have fallen over the past several decades, GC is still the fourth most common cancer and the second leading cause of cancer-related death in the world [22, 23] . Disappointingly, little improvement has been achieved within the past several decades despite advances in tumor diagnosis and treatment [24, 25] . Given the high failure rate of conventional treatment strategies, many cancer-related molecules have been characterized with the goal of developing novel anticancer strategies. eIF3f is another eIF3 subunit whose function is not well-known [18, 26] . Previous studies have demonstrated that overexpression of eIF3f inhibits cell proliferation and induces apoptosis in melanoma and pancreatic cancer cells, suggesting that downregulation of eIF3f is involved in tumorigenesis for many types of cancer [11, 16, 19] . However, there is no large sample report about the expression and clinical significance of eIF3f in human GC progression and prognosis. In this study, we investigated the expression of eIF3f in GC as well as its correlation with the clinicopathological features and prognosis.
Search related documents:
Co phrase search for related documents- anticancer strategy and cell proliferation: 1
- anticancer strategy and novel anticancer strategy: 1, 2, 3
- cancer cell and cell proliferation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- cancer cell and cell proliferation inhibit: 1, 2, 3, 4, 5, 6
- cancer cell and clinical expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cancer cell and clinical expression significance: 1, 2, 3
- cancer cell and common cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
- cancer cell and human GC progression: 1
- cancer cell and leading cause: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cancer cell and mortality incidence: 1, 2, 3, 4, 5, 6, 7
- cancer cell and mortality incidence rate: 1, 2, 3
- cancer cell and novel anticancer strategy: 1
- cancer cell and pancreatic cancer cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- cancer cell and pancreatic cancer cell melanoma: 1, 2
- cancer cell and past decade: 1, 2, 3, 4, 5, 6
- cancer cell and previous study: 1, 2
- cancer cell and treatment strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- cancer cell and tumor diagnosis: 1, 2, 3
- cancer relate and common cancer: 1
Co phrase search for related documents, hyperlinks ordered by date